Clinical Trial

Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

Study acronym: FILYRA
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this observational study is to evaluate the efficacy of fingolimod through the estimation of the annualized relapse rate (ARR) over a period of 2 years. Participants who are already taking fingolimod as part of their regular medical care for MS will answer questions about their medical history for the past 1 year and for their status for the next 2 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-28.
Trial Details
NCT Number NCT06949956
Lead Sponsor Elpen Pharmaceutical Co. Inc.
Collaborators: AHEPA University Hospital
Conditions Relapsing Remitting Multiple Sclerosis
Enrollment 140 participants
Start Date 2025-06-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-02